• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Ukraine Pharmaceuticals and Healthcare Report Q1 2013
 

Ukraine Pharmaceuticals and Healthcare Report Q1 2013

on

  • 375 views

Buy the report "Ukraine Pharmaceuticals and Healthcare Report Q1 2013" at US $1175 for a Single User PDF License from RnR Market Research Reports Library.Foreign and domestic drugmakers in Ukraine ...

Buy the report "Ukraine Pharmaceuticals and Healthcare Report Q1 2013" at US $1175 for a Single User PDF License from RnR Market Research Reports Library.Foreign and domestic drugmakers in Ukraine will see their operating margins squeezedfrom 2013 as the Ministry of Health introduces more severe limits on mark-ups.

Statistics

Views

Total Views
375
Views on SlideShare
375
Embed Views
0

Actions

Likes
0
Downloads
4
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Ukraine Pharmaceuticals and Healthcare Report Q1 2013 Ukraine Pharmaceuticals and Healthcare Report Q1 2013 Document Transcript

    • RnR Market Research Offers “Ukraine Pharmaceuticals and Healthcare Report Q1 2013”Report at US$ 1175 (Single User License). The report got published in Jan 2013 & Contains100 Pages.BMI View: Foreign and domestic drugmakers in Ukraine will see their operating margins squeezedfrom 2013as the Ministry of Health introduces more severe limits on mark-ups. Combined with the likelydevaluation ofthe hryvnia, these factors represent a very large business risk for internationaldrugmakers operating in thecountry. While Ukraine remains one of Central and Eastern Europe (CEE)smore promising pharmaceuticalmarkets given its favourable demographics and disease profile, itschronic lack of economic and politicalstability remains a critical impediment to fulfilling this potential.Headline Expenditure ProjectionsPharmaceuticals: UAH26.75bn (US$3.35bn) in 2011 to UAH30.79bn (US$3.75bn) in 2012;+15.1% in localcurrency terms and +12.1% in US dollar terms. Forecast unchanged fromQ412.Healthcare: UAH96.98bn (US$12.14bn) in 2011 to UAH109.66bn (US$13.37bn) in 2012;+13.1% in localcurrency terms and +10.1% in US dollar terms. Forecast slightly up fromQ412 on account of new historicalfigures.Medical devices: UAH6.38bn (US$799mn) in 2011 to UAH7.39bn (US$901mn) in 2012;+15.8% in localcurrency terms and +12.8% in US dollar terms. Forecast slightly up fromQ412 on account of new historicalfigures.Risk/Reward Ratings: In BMIs latest Risk/Reward Ratings Ratings (RRRs) for the 20 markets ofCentral andEastern Europe (CEE), Ukraine receives a composite pharmaceutical rating of 49.4, which isan improvementon 47.9 in Q412. The new score - propped up by the now more favourable industryrewards score - ranksUkraine 12th overall, up from 14th previously. However, risks to our forecastsexpressed in US dollars willcontinue to be posed by the weakness of local currency.Inquire for Discount of this report @http://www.rnrmarketresearch.com/contacts/discount?rname=65982Key Trends & DevelopmentsIn August 2012, a new laboratory for quality control of drugs was inaugurated in the Rivneregion of Ukraine.The laboratory will enable technicians to determine the quality of medicineson eleven parameters, comparedwith four elements earlier. The laboratory spent UAH6.8mn(US$0.82mn) from the state budget to upgrade itsprocesses, which are now automated and willprovide more precise and operational research results.In November 2012, the Volyn Regional State Administration in Ukraine instructedretailers Volynfarm,Volynfarmpostach and Salve to lower the prices of their drugs. The moveis aimed at offering affordablemedicine access to socially vulnerable groups in the country.Volynfarm has been asked to cut the cost of 100essential medicines by 10%, whileVolynfarmpostach has been instructed to give a discount of 5-10% on 88medicines. Theadministration ordered Salve to discount 104 medicines.
    • Changes in maximum mark-ups for selling medicinal products and medical devices will beimplemented fromJanuary 1 2013. The new mark-up levels will be applicable to productsincluded in the National List ofMedicinal Products and Medical Devices as well as tomandatory minimum assortment for pharmacies. Thecabinet restrictions specify a 10% purchaseprice for wholesale mark-ups, with the maximum level dependingon the level of purchase pricefor retail mark-ups. The changes include expansion of the mandatory minimumassortment ofmedicinal products and medical devices.In October 2012, Horizon Capital, a Ukrainian private equity fund, and FMO, a Dutchdevelopment investmentbank, acquired a stake in Biofarma, a leading Ukrainianpharmaceutical manufacturer. In exchange for equity,Horizon and FMO will inject capital intoBiofarma for constructing a modern plant in the capital Kyiv. Biofarmais a leading Ukrainianpharmaceutical manufacturer of plasma protein products, organic drugs andrecombinantproteins. The company is also unique among domestic manufacturers in that it isgoodmanufacturing practice (GMP)-certified for the production of plasma protein products. Thedrugmaker hashired Linde, a German engineering company with expertise in pharmaceuticalproduction, to construct thefacility and bring its manufacturing practices in line with leadingGMP standards and Western regulations.BMI Economic View: Recent economic indicator readings suggest a more aggressive economicslowdownearlier than we anticipated. We have long-held a negative outlook for Ukrainian economicactivity, on ournegative outlook for global metallurgical markets, a hryvnia devaluation and a weakerexternal demand. As aresult, we have downgraded our real GDP growth forecasts to -0.1% and 1.0% in2012 and 2013 respectively,from a previous forecast of 2.0% and 0.9%.BMI Political View: In line with our expectations, the ruling Party of Regions has held onto its majorityfollowingthe parliamentary elections on October 28 2012, providing President Viktor Yanukovych with apro-presidential majority. With the Party of Regions majority now secured and the next election threeyears away,the government will turn its long overdue focus to economic policy and reform, including asyet unfulfilledpromises to the International Monetary Fund (IMF). This could potentially lead to anunfreezing of UkrainesUS$16.4bn Stand-By Arrangement (SBA) with the Fund, which would provide aboon to domestic economicstability, as well as reducing default risks and lowering internationalborrowing costs. Energy policy andcurrency stability will present major-near term obstacles to economicgrowth and the government will have toundertake difficult decisions to avoid a full-blown crisis.Buy your report copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=65982Table Of ContentsExecutive SummarySWOT AnalysisUkraine Pharmaceutical And Healthcare Industry SWOTUkraine Political SWOTUkraine Economic SWOTUkraine Business Environment SWOTPharmaceutical Risk/Reward RatingsTable: Emerging Europe - Regional Pharmaceutical Risk/Reward Ratings, Q113RewardsRisksMarket OverviewRegulatory RegimeRecent Regulatory AmendmentsPharmaceutical AdvertisingIntellectual Property Issues
    • Counterfeit DrugsPricing RegimeRecent Pricing Regime DevelopmentsReimbursement RegimeDrug Tendering RegimeIndustry DevelopmentsEpidemiologyTable: Selected Causes of Death, 2005-2010 (000s)Table: Morbidity by Selected Diseases, 2005-2010 (000s)Public Health DevelopmentsHealthcare SystemHealthcare FundingHealthcare System ReformHealth Insurance DevelopmentsHealthcare ProvisionTable: Number of Outpatient Facilities, 1995-2010Research and Development (R&D)Clinical TrialsMedical DevicesIndustry Forecast ScenarioPharmaceutical Market ForecastTable: Pharmaceutical Sales, Historical Data and ForecastsHealthcare Market ForecastTable: Healthcare Expenditure Trends, Historical Data and ForecastsTable: Government Healthcare Expenditure Trends, Historical Data and ForecastsTable: Private Healthcare Expenditure Trends, Historical Data and ForecastsKey Growth Factors - MacroeconomicPrescription Drug Market ForecastTable: Ukraine Prescription Drug Market Indicators, Historical Data and ForecastsPatented Drug Market ForecastTable: Patented Drug Market Indicators, Historical Data and ForecastsGeneric Drug Market ForecastTable: Generics Drug Market Indicators, Historical Data and ForecastsOTC Medicine Market ForecastTable: OTC Medicine Market Indicators, Historical Data and ForecastsPharmaceutical Trade ForecastTable: Pharmaceutical Trade Data And Forecasts (US$mn)Table: Pharmaceutical Trade Data And Forecasts (UAHmn)Medical Device Market ForecastTable: Medical Device Market Indicators, Historical Data and ForecastsOther Healthcare DataKey Risks to ForecastsCompetitive LandscapePharmaceutical IndustryTable: Retail Pharmacy Sales Value & Volume, 2004-2010 (Million)Table: Retail Pharmacy Sales Value by Leading Company, 2007-2010 (UAH Million)Table: Retail Pharmacy Sales Value & Volume by Origin, 2010 (Million)Table: Retail Pharmacy Sales Volume by Leading Company, 2010 (Million)Domestic Pharmaceutical SectorForeign Pharmaceutical SectorTable: Association of International Manufacturers (AIPM) Ukraine Members, 2011Recent Company Activities
    • Pharmaceutical WholesalePharmaceutical RetailCompany ProfilesArteriumGedeon RichterKrkaLek (Novartis/Sandoz)Table: Ukraines Population By Age Group, 1990-2020 (000)Table: Ukraines Population By Age Group, 1990-2020 (% of total)Table: Ukraines Key Population Ratios, 1990-2020Table: Ukraines Rural And Urban Population, 1990-2020GlossaryBMI MethodologyHow We Generate Our Pharmaceutical Industry ForecastsPharmaceuticals Risk/Reward Ratings MethodologyRatings OverviewTable: Pharmaceutical Risk/Reward Ratings IndicatorsWeightingTable: Weighting Of ComponentsSourcesFor more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441Website: http://www.rnrmarketresearch.com/